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BACKGROUND AND PURPOSE
Ulinastatin (UTI), a serine protease inhibitor, was recently found to have an anti-inflammatory action. However, the
mechanisms mediating this anti-inflammatory effect are not well understood. This study tested the hypothesis that UTI
suppresses allergic inflammation by inducing the expression of haem oxygenase 1 (HO1).

EXPERIMENTAL APPROACH
Control mice and mice sensitized (on days 1, 9 and 14) and challenged (on days 21 to 27) with ovalbumin (OVA) were
treated with UTI. The effects of UTI on basal expression of HO1 and that induced by OVA challenge were examined. The
involvement of UTI-induced HO1 expression in anti-inflammatory and antioxidant effects of UTI was also evaluated.

KEY RESULTS
UTI markedly increased basal HO1 protein expression in lungs of control mice in a time- and dose-dependent manner, and
augmented HO1 protein expression induced by OVA. The up-regulation of HO1 mediated by UTI in sensitized and
OVA-challenged mice was associated with reduced airway inflammation, alleviated tissue injury, reduced oxidant stress and
enhanced antioxidant enzyme activities. Inhibition of HO1 activity using HO1 inhibitor, zinc protoporphyrin, attenuated
inhibitory effects of UTI on inflammation and oxidant stress, and its stimulant effects on antioxidant enzyme activities.
Mechanistic analysis showed that UTI increased nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2),
stimulated Nrf2 DNA binding activity and concomitantly up-regulated HO1 mRNA expression.

CONCLUSIONS AND IMPLICATIONS
UTI is a potent and naturally occurring inducer of HO1 expression. HO1 up-regulation contributes significantly to the
anti-inflammatory and organ-protective effects of UTI, which has important research and therapeutic implications.

Abbreviations
BALF, bronchoalveolar lavage fluids; CO, carbon monoxide; DCFDA, 2′, 7′-dichlorofluorescein diacetate; Dex,
dexamethasone; EBD, Evans blue dye; HO1, haem oxygenase 1; MDA, malondialdehyde; Nrf2, nuclear factor erythroid
2-related factor 2; OVA, ovalbumin; SOD, superoxide dismutase; TAOC, total antioxidant capacity; UTI, ulinastatin
(urinary trypsin inhibitor); ZnPP, zinc protoporphyrin
© 2014 The British Pharmacological Society
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Table of Links
TARGETS

LIGANDS

haem oxygenase 1

dexamethasone
Evans blue dye

This Table lists protein targets and ligands which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and the Concise Guide to PHARMACOLOGY 2013/14 (Alexander et al., 2013).

Introduction
Ulinastatin was originally purified as a serine protease inhibitor (Muramatu et al., 1980) and is also known as urinary
trypsin inhibitor (UTI). Recently, UTI was found to have
anti-inflammatory and cytoprotective actions. UTI gene deletion exacerbated systemic inflammation and organ injury in
endotoxaemic mice (Inoue et al., 2005a,b). Exogenous
administration of UTI to endotoxaemic animals inhibited
inflammatory mediator production, reversed systemic hypotension (Molor-Erdene et al., 2005), prevented intravascular
coagulation (Takano et al., 2009) and ameliorated multiple
organ injury (Takano et al., 2009; Zhang et al., 2011). UTI
protected against ischaemia-reperfusion (Yano et al., 2003;
Koga et al., 2010), haemorrhage (Masuda et al., 2003), smoke
inhalation (Qiu et al., 2012) or organ injury induced by sea
water inhalation (Rui et al., 2012). UTI has also been shown
to have beneficial effects in patients with severe sepsis, traumatic brain injury and acute Kawasaki disease (Chen et al.,
2009; Kanai et al., 2011; Tu et al., 2012).
Although anticoagulant and organ-protective effects of
UTI may be partially explained by inhibition of protease
activities, the anti-inflammatory action of UTI cannot be
fully explained by protease inhibition. Mechanisms mediating the anti-inflammatory action of UTI remain to be
elucidated.
Investigation into the effects of UTI on inflammation and
organ injury has thus far been focused primarily on
neutrophil-mediated responses. The effects of UTI on other
types of inflammation, including allergic inflammation, have
not been studied. Allergic airway inflammation differs significantly from sepsis-associated inflammation in cause, nature,
extent of inflammation, as well as cell types and mediators
involved. Allergic inflammation is generally associated with
eosinophil infiltration (Barnes, 1996; Agrawal and Shao,
2010), whereas endotoxaemic inflammation is characterized
by neutrophil infiltration. Studying the effect of UTI on allergic inflammation may gain new insights into other mechanisms underlying UTI’s anti-inflammatory action.
The haem oxygenase 1 (HO1)/carbon monoxide (CO)
pathway is an important antioxidant and anti-inflammatory
defense mechanism (Ferrándiz and Devesa, 2008; Gozzelino
et al., 2010; Raval and Lee, 2010). Increased HO1 expression
has been consistently demonstrated to be associated with
beneficial effects in a variety of pathological conditions
(Ferrándiz and Devesa, 2008; Gozzelino et al., 2010; Raval
and Lee, 2010). UTI may exert its anti-inflammatory and
4400
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organ-protective actions by up-regulating HO1 expression.
However, UTI as a new HO1 inducer remains to be proven.
The role of the HO1/CO pathway in mediating the antiinflammatory and organ-protective actions of UTI is unclear.
The purpose of this study was threefold: firstly, to clarify
if UTI is anti-inflammatory and tissue-protective in allergic
inflammation in an ovalbumin (OVA)-sensitized and challenged mouse model; secondly, to demonstrate that UTI is a
novel HO1 inducer; and thirdly, to define the role of HO1
up-regulation in mediating UTI’s anti-inflammatory and
antioxidant effects. We demonstrated for the first time that
UTI is a potent and naturally occurring inducer of HO1.
HO1 up-regulation contributes significantly to the antiinflammatory and organ-protective effects of UTI. Our study
provides new insights into the mechanisms of action of UTI.

Methods
Animal studies
All animal study protocols were approved by Institutional
Animal Care and Use Committee, and complied with the
regulations of the ministry of health of China and the US
National Institute of Health guidelines. All studies involving
animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny
et al., 2010; McGrath et al., 2010). FVB mice (8–10 weeks-old)
were obtained from Vital River Laboratory Animal Technology (Beijing, China), housed five mice per cage, and kept
under a 12 h light/dark cycle and constant temperature 21 ±
2oC, humidity, 30–70%, with food and water provided ad
libitum. The total number of mice used was 233. After 1 week
of acclimatization, mice were randomly divided into study
groups. Mice in the non-sensitized control group were shamsensitized by injection with PBS and sham-challenged with
PBS inhalation. Mice in the other groups were sensitized by
i.p. injection of OVA (emulsified in 2.5 mg aluminum
hydroxide in PBS) 25 μg·per mouse, on days 1, 9 and 14, and
challenged by inhalation of 1% OVA in PBS for 20 min day-1
on days 21 to 27. Mice in OVA + UTI or OVA + Dex groups
were administered UTI (100 000 U·kg−1·day−1, i.p.) or Dex
(1 mg·kg−1·day−1, i.p.) on days 21 to 27. Mice in OVA + UTI +
ZnPP group were injected with ZnPP (20 mg·kg−1·day−1, i.p.)
1 h before each UTI administration. On day 28, airway reactivity or lung endothelial permeability was measured, or
bronchoalveolar lavage (BAL) was performed followed by the
collection of blood and tissue samples.

Ulinastatin induces haem oxygenase 1 expression

For OVA inhalation, mice were placed in a plexiglas inhalation chamber maintained under normoxic and normocapnic conditions. Aerosolized OVA or PBS was delivered using an
ultrasonic nebulizer (NE-U12, Omron Corp., Beijing, China)

Measurement of airway responsiveness

Mice were anaesthetized with nembutal (60 mg·kg−1, i.p.);
absence of withdrawal reflex to toe pinch in combination
with assessment of jaw “tone”, heart rate and respiratory rate
were used to assess depth of anaesthesia. The trachea was
cannulated and the mice were mechanically ventilated and
then placed in a sealed whole body plethysmograph connected to an AniRes2005 data collection and analysis system
(BestLab, Beijing, China) for monitoring respiratory mechanics. Transpulmonary resistance was recorded at baseline, and
after aerosolized PBS or three doses of aerosolized methacholine (3, 9 and 27 mg·mL−1). Airway reactivity was measured as
changes in transpulmonary resistance provoked by each dose
of methacholine.

Counting cells in the bronchoalveolar lavage
fluid (BALF)
BAL was performed by delivering 0.8 mL of prewarmed PBS
into the trachea followed by gentle suction. Following
removal of debris, pooled BALF from three BALs was centrifuged. The pellet was resuspended in PBS, and total cell
number was counted with haemocytometer after cell viability
determination by trypan blue exclusion test. For differential
cell counts, cells were centrifuged onto cytospin slides,
differentially stained with Diff-Quik® stain reagent (Beyotime
Institute of Biotechnology, Nanjing, China) and counted.

Histology and immunofluorescence staining
Mouse nasal cavity and lungs were fixed in 10% formalin and
processed or were embedded in optimal cutting temperature
compound and snap-frozen. For histological analysis,
paraffin-embedded sections (4 μm) were stained with haematoxylin and eosin. For HO1 or nuclear factor erythroid
2-related factor 2 (Nrf2) immunofluorescence staining, lung
cryosections (6 μm) were fixed with paraformaldehyde, permeabilized and stained with HO1 or Nrf2 antibody (Abcam,
Cambridge, MA, USA) followed by staining with fluorescein
isothiocyanate-conjugated secondary antibody. Nuclei were
counterstained with DAPI.

Measurement of lung endothelial permeability
Lung microvascular endothelial permeability was assessed
using EBD leakage index as a marker, as previously described
(Wang le et al., 2002). Tissue EBD content (ng EBD·mg−1 dry
tissue) was calculated by comparing tissue supernatant A620
readings with an EBD standard curve.

Measurements of serum level of IgE, BALF
levels of cytokine, oxidant stress markers and
antioxidant activities, and lung tissue levels
of protein carbonyl content and
malondialdehyde (MDA)
Serum levels of total and OVA-specific IgE, BALF levels of IL-4,
IL-5 and IFN-γ, or BALF level of eotaxin-1 were measured
using mouse IgE, IL-4, IL-5 and IFN-γ ELISA kits (Bethyl Laboratories, Montgomery, AL, USA) or eotaxin-1 ELISA kit
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(Yuanye, Shanghai, China). BALF level of total antioxidant
capacity (TAOC), glutathione (GSH), superoxide dismutase
(SOD) and catalase activities were determined using assay kits
(Beyotime Institute of Biotechnology, Nanjing, China).
BALF leukocyte reactive oxygen species activity was measured using a 2′, 7′-dichlorofluorescein diacetate (DCFDA) fluorescence probe (Beyotime Company, Shanghai, China). One
millilitre of BALF containing 1 × 105 leukocytes was mixed and
incubated with 20 μM DCFDA at 37°C for 20 min. Fluorescence intensity of the oxidized DCFDA was measured using a
spectrophotometer (Perkin-Elmer, Waltham, MD, USA).
Lung tissue levels of protein carbonyl content or MDA
were determined using a protein carbonyl content assay
kit (Abcam) or a MDA assay kit (Beyotime Institute of
Biotechnology).

Western blot
Total, cytoplasmic or nuclear protein was extracted from
lungs. Equal amounts of proteins (25 μg) were separated on
10% SDS-PAGE gels and transferred to a PVDF membrane.
Western blot was performed as previously described (Ye et al.,
2008) using eosinophil peroxidase, HO1, Nrf2, β-actin or
lamin specific antibodies (Abcam; Zymed, Carlsbad, San
Diego, CA, USA or Bioss Inc., Beijing, China).

Real-time PCR
RNA was isolated from lungs using the RNeasy mini kit
(Qiagene, Germantown, MD, USA). Reverse transcription was
performed using Sensiscript RT kit (Promega, Madison, WI,
USA). Real-time PCR was performed in an ABI Prism 7900
sequence detection system (Applied Biosystems, Foster City,
CA, USA) using SYBR Green PCR master mix following a
standard protocol. The primer sequences are provided in Supporting information Table S1. Results were analysed using the
2−ΔCt method. HO1, IL-4, IL-5 or IFN-γ mRNA was normalized
to GAPDH mRNA.

Measurements of Nrf2 and NF-κB
binding activity
Nuclear protein was prepared from lungs. Nrf2 or NF-κB DNA
binding activity was measured using Nrf2 (antioxidantresponse element) or NF-κB electrophoretic mobility shift
assay Kit (Signosis, Santa Clara, CA, USA).

Statistical analysis

Data are expressed as means ± SD and analysed
ANOVA followed by post hoc analysis using
method, or were analysed by Kruskal–Wallis test
Mann–Whitney U-test. A P-value less than 0.05
ered significant.

by one-way
Holm-Sidak
followed by
was consid-

Chemicals
Dexamethasone (Dex), Evans blue dye (EBD), OVA, methacholine, UTI and zinc protoporphyrin (ZnPP) were purchased
from Sigma-Aldrich (St Louis, MO, USA).

Results
UTI inhibits allergic airway inflammation
We examined the anti-inflammatory effect of UTI on allergic
inflammation in comparison with the effect of Dex, which
British Journal of Pharmacology (2014) 171 4399–4412
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Figure 1
UTI suppresses allergic inflammation. At 24 h after final OVA challenge, numbers of neutrophils, eosinophils and lymphocytes in bronchoalveolar
lavage fluid (BALF) were counted, BALF levels of IL-4, IL-5, eotaxin-1 and IFN-γ proteins were measured, and lung tissue levels of eosinophil
peroxidase (EPO) were determined in mice of non-sensitized control (Con), ovalbumin sensitization and challenge (OVA), OVA + UTI or OVA plus
dexamethasone (OVA + Dex) group. (A) UTI or Dex treatment inhibits OVA sensitization and challenge-induced increase in BALF leukocyte count.
Means ± SD of 10 mice per group. (B) Western blot photographs show that UTI or Dex treatment inhibits OVA sensitization and challenge-induced
lung tissue level of EPO. (C) The Western blot EPO bands were quantified using densitometry and expressed as fold change over control group.
Means ± SD of five mice per group. (D to G) UTI or Dex treatment reverses OVA challenge-induced increase in BALF eoxaxin-1, IL-4 and IL-5, and
decrease in BALF IFN-γ. Means ± SD of 10 mice per group. *P < 0.05, compared with control group. #P < 0.05, compared with OVA alone group.
4402
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Figure 2
UTI ameliorates OVA sensitization and challenge-induced pathologies and improves lung function. At 24 h after final OVA challenge, paraffinembedded sections of nasal mucosa and lungs were stained with haematoxylin and eosin (H&E); lung endothelial permeability measured and airway
reactivity to methacholine were also assessed. (A) Representative H&E staining images of nasal mucosa sections. Section from sensitized and
challenged mice (OVA) exhibited increased inflammatory cell infiltration, epithelial derangement, epithelial deciliation and goblet cell hypertrophy.
These histological changes were not obvious in sections from OVA + UTI or OVA + Dex groups of mice. Scale bar = 40 μm. (B) Representative H&E
staining images of lung sections. Section from OVA-sensitized and challenged mice displayed inflammatory cell infiltration in bronchial and alveolar
walls. These histological changes were ameliorated in sections from OVA + UTI or OVA + Dex groups of mice. Scale bar = 20 μm. (C) UTI reduces OVA
sensitization and challenge-induced lung endothelial permeability. Lung endothelial permeability, measured using EBD leakage index as an indicator,
increased significantly in OVA alone group, which was prevented in OVA + UTI and OVA + Dex group. Means ± SD of 10 mice per group. *P < 0.05,
compared with control group. #P < 0.05, compared with OVA alone group. (D) UTI reduces OVA sensitization and challenge-induced airway
hyperactivity. Airway reactivity to aerosolized methacholine increased significantly in OVA alone group, which was prevented in OVA + UTI and OVA
+ Dex group. Means ± SD of five mice per group. *P < 0.05, compared with control group. #P < 0.05, compared with OVA alone group.
British Journal of Pharmacology (2014) 171 4399–4412
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is a well-known anti-inflammatory agent and known
up-regulator of HO1 expression (Xu et al., 2008). Consistent
with the characteristics of allergic inflammation, OVAsensitized and challenged mice displayed elevated serum
levels of total and OVA-specific IgE (Supporting information
Figure S1), higher numbers of BALF eosinophils and a higher
lung tissue level of eosinophil peroxidase (Figure 1A–C),
higher BALF levels of IL-4, IL-5 and eotaxin, and lower BALF
level of IFN-γ (Figure 1D–G). These mice also had higher
levels of IL-4 and IL-5, and a lower level of IFN-γ mRNA
expression in lungs (Supporting information Figure S2).
Treatment of OVA-sensitized and challenged mice with UTI
reduced serum IgE level (Supporting information Figure S1),
decreased airway and lung eosinophil infiltration (Figure 1A,
B) and reversed the changes in BALF levels of cytokines and
lung tissue levels of cytokine mRNAs (Figure 1 and Supporting information Figure S2). Dex had similar effects (Figure 1
and Supporting information Figures S1 and S2).

UTI ameliorates OVA sensitization and
challenge-induced airway and
lung pathologies
Because allergic inflammation affects both the nose and
airway (Jeffery and Haahtela, 2006), we examined the effects
of UTI on OVA sensitization and challenge-induced pathologies in nose, bronchi and lungs. In nasal mucosa, epithelial
cilia loss, epithelial derangement, goblet cell hypertrophy
and mucosal inflammatory cell infiltration were observed
(Figure 2A). In lungs, inflammatory cell infiltration in bronchial and alveolar walls (Figure 2B), which was associated
with increased BALF cell counts, and increased endothelial
permeability (Figure 2C) were found. UTI treatment ameliorated these histological changes and prevented the increase
in endothelial permeability (Figure 2). Dex treatment provided similar protective effects (Figure 2).

UTI attenuates OVA sensitization and
challenge-induced airway hyperreactivity
Suppression of allergic inflammation and pathologies
resulted in an improved lung function. OVA-sensitized and
challenged mice displayed an increased airway reactivity to
methacholine inhalation, which was attenuated in UTI- or
Dex-treated mice (Figure 2D).

UTI attenuates OVA sensitization and
challenge-induced oxidant stress
We examined the possibility that UTI exerts its antiinflammatory effect by regulating tissue oxidant and antioxidant balance. We measured markers of tissue oxidative stress,
BALF leukocyte reactive oxygen species activity, lung tissue
MDA level and lung protein carbonyl content. OVAsensitized and challenged mice showed elevated levels of the
three oxidant stress markers, which were suppressed by treatment with UTI or with Dex to a lesser extent (Figure 3).

UTI enhances antioxidant capacity
UTI also enhances endogenous antioxidant capacity. Mice in
the OVA-sensitized and challenged group showed significantly reduced BALF levels of GSH, TAOC, SOD and catalase
4404
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Figure 3
UTI inhibits OVA sensitization and challenge-induced oxidative stress. At 24 h after final OVA challenge, BALF leukocyte reactive
oxygen species (ROS) activity (A) and lung tissue protein carbonyl
content (B) and malondialdehyde (MDA) level (C) were measured
using DCFDA fluorescence probe and expressed as fluorescence
intensity, and using protein carbonyl content and MDA assay kits.
Means ± SD of 10 mice per group. *P < 0.05, compared with control
group. #P < 0.05, compared with OVA alone group.

activities, which were prevented by UTI treatment (Figure 4).
More importantly, UTI treatment increased BALF GSH, TAOC,
SOD or catalase activity to a level that was higher than
control (Figure 4), suggesting that UTI stimulates endogenous
antioxidant capacity. Dex had similar effects. Thus, UTI treatment reduces tissue oxidant stress and enhances endogenous
antioxidant capacity.

UTI induces HO1 protein expression
We explored the possibility that UTI exerts its antioxidant
and anti-inflammatory effects by inducing HO1 expression.

Ulinastatin induces haem oxygenase 1 expression
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Figure 4
UTI enhances endogenous antioxidant capacity. At 24 h after final OVA challenge, BALF levels of total superoxide dismutase (SOD) actvity (A),
catalase activity (CAT, B), glutathione (GSH, C) and total antioxidant capacity (TAOC, D) were measured. Means ± SD of 10 mice per group.
*P < 0.05, compared with control (Con) group. #P < 0.05, compared with OVA alone group.

Treatment of control mice with UTI increased the basal level
of HO1 protein expression in lungs in a time- and dosedependent manner (Figure 5). OVA sensitization and challenge increased, to a significantly lesser extent, the lung tissue
level of HO1 protein. Treatment of OVA-sensitized and challenged mice with UTI increased HO1 protein expression by
approximately twofold (Figure 6A, B). Immunofluorescence
staining showed that UTI treatment of sensitized and challenged mice increased the number of HO1-positive cells in
the lungs (Figure 6C). Stimulation of HO1 expression was not
mediated by the excipients of UTI. Excipients at the dose
equivalent to the highest concentration of UTI had no effects
on HO1 expression and on OVA-induced oxidative stress
(Supporting information Figure S3). Thus, UTI stimulates
basal and augments OVA-induced HO1 expression, and is an
inducer of HO1. Treatment of OVA-sensitized and challenged
mice with Dex also increased HO1 expression but to a lesser
extent than HO1 (Figure 6).

Inhibition of HO1 activity attenuates the
anti-inflammatory and antioxidant activities
of UTI
To verify the link between UTI-induced HO1 up-regulation
and UTI-mediated anti-inflammatory and antioxidant effects,
we examined the effect of inhibiting HO1 activity using ZnPP,
a widely used HO1 inhibitor (Bonkovsky et al., 1990; Lee and

Chau, 2002), on the anti-inflammatory and antioxidant
activities of UTI. UTI treatment reversed OVA-induced
increases in BALF IL-4 and lung tissue MDA levels, and
decreases in BALF IFN-γ level and SOD activity (Figure 7).
Co-treatment of sensitized and challenged mice with UTI
plus ZnPP attenuated the inhibitory effects of UTI on IL-4 and
MDA production and its stimulant effects on IFN-γ and SOD
activity (Figure 7). UTI inhibited OVA-induced decreases in
BALF levels of GSH, TAOC and catalase activity, effects that
were reversed by co-treatment with ZnPP (Supporting information Figure S4). These results suggest a link between UTIinduced up-regulation HO1 and its anti-inflammatory and
antioxidant effects.

UTI stimulates HO1 mRNA expression and
Nrf2 DNA binding activity
UTI treatment increased basal HO1 mRNA expression in
control mice and augmented OVA-induced HO1 mRNA
expression in sensitized and challenged mice (Figure 8A), suggesting that UTI stimulates HO1 gene transcription.
HO1 gene transcription is mediated by Nrf2, which, upon
stimulation, is translocated from the cytoplasm into the
nucleus, inducing HO1 gene transcription (Kobayashi and
Yamamoto, 2005). We therefore examined the effect of UTI
on Nrf2 activation. Western blot analysis demonstrated that
UTI treatment of control or OVA-challenged mice increased
British Journal of Pharmacology (2014) 171 4399–4412
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activity. UTI attenuated the increased NF-κB DNA binding
activity induced by OVA sensitization and challenge (Supporting information Figure S6).

Discussion and conclusions

Figure 5
UTI stimulates basal HO1 protein expression. (A and C) Western blot
photographs showing that UTI dose- and time-dependently
increased basal HO1 protein expression in control lungs. (B and D)
Western blot HO1 bands were quantified using densitometry and
expressed as fold increase over control group. Means ± SD of four
mice per group. *P < 0.05, compared with control group.

nuclear, and decreased cytoplasmic levels of Nrf2 in parallel
in lungs (Figure 8B–D). Immunofluorescence staining showed
that lung sections from OVA + UTI mice had increased
numbers of Nrf2-positive nuclei (Supporting information
Figure S5), indicating an increased nuclear translocation of
Nrf2. EMSA revealed an increased Nrf2 DNA binding activity
in lungs from UTI and OVA + UTI groups of mice (Figure 8E).

UTI inhibits NF-κB DNA binding activity
The NF-κB pathway is a major inflammatory way (Liu and
Malik, 2006). We also examined the effect of UTI on NF-κB
4406
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A major finding of this study is that UTI is a potent inducer of
HO1 expression. UTI markedly increased basal HO1 protein
expression in control lungs in a time- and dose-dependent
manner. UTI augmented the increased expression of HO1
induced by OVA sensitization and challenge. UTI, at the
highest dose tested, increased basal HO1 protein level by
approximately 3.5-fold. Thus, we demonstrated that UTI is a
novel and naturally occurring inducer of HO1 expression.
Two previous reports have examined the effect of UTI on
HO1 expression. One study claimed that treatment of rats
with UTI for 4 h augmented oleic acid-induced HO1 expression. However, in that study, lung HO1 level was analysed by
immunohistochemical staining, which is quantifiable (Jin
et al., 2007). The other study found that UTI had no effect on
basal and hemin-induced HO1 expression in a septic shock
model (Yu and Yao, 2008). Differences in the duration and
dose of UTI treatment may explain the discrepancies between
the previous and our current studies. In the previous studies,
rats were treated with UTI for a few hours (Jin et al., 2007; Yu
and Yao, 2008), whereas we found that 48 h of UTI treatment
was needed to induce HO1 expression in vivo.
Our findings could have therapeutic applications. HO1 is
the rate-limiting enzyme that degrades haem into CO and
biliverdin. The HO1/CO pathway is an important antioxidant
and anti-inflammatory defense mechanism (Ferrándiz and
Devesa, 2008; Gozzelino et al., 2010; Raval and Lee, 2010).
The induction of HO1 has consistently been shown to be
associated with beneficial effects in a variety of pathological
conditions (Ferrándiz and Devesa, 2008; Gozzelino et al.,
2010; Raval and Lee, 2010). However, HO1 is an inducible
enzyme whose expression is minimal in most tissues under
physiological conditions. Controlled up-regulation of this
enzyme is a major means of activating the HO1/CO pathway
and achieving potential therapeutic goals. Although several
chemical HO1 inducers have been reported (Ferrándiz and
Devesa, 2008), UTI has an advantage over these chemicals as
it is an endogenous peptide that has been in clinical use for
over 30 years with no significant side effects reported.
The mechanisms by which UTI induces HO1 expression
remain to be elucidated. HO1 gene transcription is mainly
regulated by Nrf2 (Kobayashi and Yamamoto, 2005). Nrf2
is retained in the cytoplasm by binding to Kelch-like ECH
associating protein 1, which facilitates Nrf2 ubiquitination
and degradation by ubiquitin proteasome system. Upon
stimulation, Nrf2 is dissociated from Kelch-like ECH associating protein 1, translocated into the nucleus and binds to
the antioxidant-response element on the HO1 gene promoter, leading to HO1 gene transcription (Kobayashi and
Yamamoto, 2005; Kensler et al., 2007). We demonstrated that
UTI increased the translocation of Nrf2 into the nucleus,
stimulated Nrf2 DNA binding activity and concomitantly
up-regulated HO1 mRNA expression. This result suggests that
UTI may stimulate Nrf2-mediated HO1 mRNA expression.
There are several possible ways that UTI could activate Nrf2.

Ulinastatin induces haem oxygenase 1 expression
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Figure 6
UTI augments OVA-induced HO1 protein expression. At 24 h after final OVA challenge, lung tissue level of HO1 protein was determined. (A)
Western blot photographs show that UTI or Dex augments OVA-induced HO1 protein expression. (B) Western blot HO1 bands were quantified
using densitometry and expressed as fold increase over control group. Means ± SD of five mice per group. *P < 0.05, compared with control group.
#P < 0.05, compared with OVA alone group. (C) Representative photographs of immunofluorescence staining show UTI increases HO1 expressing
cells. Lung cryosections were prepared 24 h after final OVA challenge, and immunofluorescence stained with HO1 antibody and nuclear
counterstained with DAPI. Specificity of HO1 staining was confirmed using isotype control antibody. OVA sensitization and challenge caused an
increase, and OVA + UTI caused a further increase in number of HO1 positive cells. Scale bar = 20 μm.
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Figure 7
Inhibition of HO1 activity attenuates UTI’s anti-inflammatory and antioxidant activities. Mice in OVA + UTI + ZnPP group were injected with ZnPP
(20 mg·kg−1·day−1, i.p.) 1 h before each UTI injection. At 24 h after final OVA challenge, BALF levels of IL-4 (A), IFN-γ (C) and total SOD activity
(D), and lung tissue level of MDA (B) were measured. Means ± SD of 10 mice per group. *P < 0.05, compared with control group. #P < 0.05,
compared with OVA alone group. $P < 0.05, compared with OVA + UTI group.

Many signalling molecules, including Nrf2 and HO1, are
degraded by the ubiquitin proteasome system. UTI is a serine
protease inhibitor and might inhibit Nrf2 degradation. UTI
may directly interact with Nrf2 protein to alter its function
through an, as yet, unknown mechanism. Alternatively, UTI
might directly inhibit proteases involved in the degradation
of HO1 or upstream signalling molecules that mediate HO1
expression. These potential mechanisms can be important
and warrant further investigation.
The second finding of this study is that UTI is also an
effective anti-inflammatory agent against allergic inflammation. Previous studies have reported that UTI protected
against neutrophil-mediated inflammation and organ injury
(Masuda et al., 2003; Inoue et al., 2005a,b; Molor-Erdene
et al., 2005; Takano et al., 2009; Koga et al., 2010; Qiu et al.,
2012; Rui et al., 2012). However, the effect of UTI on allergic
inflammation has not been studied. Allergic airway inflammation is type 2 T cell-mediated eosinophilic inflammation
(Barnes, 1996; Agrawal and Shao, 2010), which differs
from neutrophil-mediated inflammation in both cellular
mechanisms and mediators involved. We demonstrated here
that UTI treatment of OVA-sensitized and challenged mice
decreased the serum level of OVA-specific IgE, reduced
eosinophil infiltration, decreased BALF and lung tissue levels
of cytokines and ameliorated many of the pathological signs
of inflammation. Our findings extend those from previous
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studies by demonstrating that UTI acts as an antiinflammatory in allergic inflammation.
Up-regulation of HO1 expression may contribute significantly to the antioxidant and anti-inflammatory effects of
UTI. We demonstrated here that UTI treatment up-regulated
HO1 expression, and concomitantly inhibited inflammation,
alleviated tissue oxidant stress and mitigated tissue damage in
airway and lungs of OVA-sensitized and challenged mice. The
HO1/CO pathway is a major antioxidant defense pathway
(Ferrándiz and Devesa, 2008; Gozzelino et al., 2010; Raval
and Lee, 2010). Numerous previous studies have demonstrated anti-inflammatory and antioxidant effects of HO1 in
allergic inflammation (Xia et al., 2006; Ferrándiz and Devesa,
2008; Gozzelino et al., 2010; Raval and Lee, 2010; Sheikh
et al., 2011) and in systemic inflammatory syndrome (Tanaka
et al., 2010). More importantly, we demonstrated that inhibition of HO1 activity attenuated the inhibitory effect of UTI
on inflammation and tissue oxidant stress, and the stimulant
effects of UTI on endogenous antioxidant capacity. Taken
together, our results demonstrate that UTI may exert its antiinflammatory effect by inducing HO1 expression. We also
demonstrated that UTI inhibited OVA-induced NF-κB activity, which may also contribute to its anti-inflammatory
effects. However, this effect was rather weak.
A previous study reported that UTI augments hydrogen
sulfide-induced Nrf2 mRNA expression (Ge et al., 2012). We
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Figure 8
UTI stimulates Nrf2 activity and up-regulates HO1 mRNA expression. At 24 h after final OVA challenge, cytoplasmic and nuclear levels of Nrf2
protein, Nrf2 DNA binding activity and tissue level of HO1 mRNA in lungs were determined. (A) Q-RT-PCR shows that UTI up-regulates HO1 mRNA
expression in lungs. HO1 mRNA was normalized to GAPDH mRNA. Means ± SD of five mice per group. *P < 0.05, compared with control group.
#P < 0.05, compared with OVA alone group. (B) Western blot photographs show that UTI increases nuclear and decreases cytoplasmic Nrf2
content, indicating Nrf2 nuclear translocation. (C and D) Western blot Nrf2 bands were quantified using densitometry and expressed as fold
increase or decrease over control group. Means ± SD of four mice per group. *P < 0.05, compared with control group. #P < 0.05, compared with
OVA alone group. (E) EMSA photograph shows that UTI stimulates Nfr2 DNA binding activity in lungs. Representative of three independent
experiments.
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found no evidence that UTI increases Nrf2 protein expression, even though UTI stimulated Nrf2 nuclear translocation
and Nrf2 DNA binding activity. It is possible that the antioxidant and anti-inflammatory effects of UTI are attributable
to increased Nrf2 activity, but not to increased Nrf2 expression. In addition to HO1, Nrf2 mediates the transcription of
many antioxidant genes. The contributions of these gene
products to the antioxidant and anti-inflammatory effects of
UTI warrant further investigation.
Our observation that Dex up-regulated HO1 is consistent
with results from previous studies, where it was shown that
Dex up-regulates HO1 in a rat lungs (Xu et al., 2008) and in
human monocytes (Yamazaki et al., 2007). However, in contrast, Dex has been shown to repress IL-6-mediated HO1
up-regulation in cultured endothelial cells (Deramaudt et al.,
1999). Differences in cell types, models, experimental conditions and mechanisms of action of Dex may all contribute to
these discrepancies.
In conclusion, UTI is a potent and naturally occurring
inducer of HO1 expression. Up-regulation of HO1 by UTI
may involve Nrf2 activation. UTI inhibits allergic inflammation in an OVA-sensitized and challenged mouse model. Activation of the HO1 antioxidant pathway may contribute to
the anti-inflammatory and tissue-protective effects of UTI.
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Figure S1 UTI reduces serum levels of total and OVA-specific
IgE. Mice in sham sensitized control group (Con) were sham
sensitized and challenged with PBS. Mice in ovalbumin sensitization and challenge group (OVA), OVA plus UTI (OVA +
UTI) or OVA plus dexamethasone (OVA + Dex) groups were
sensitized with OVA (25 μg·mouse−1·day−1, i.p.) on days 1, 9
and 14, and challenged by inhalation of 1% OVA for 20 min
per day on days 21 to 27. Mice in OVA + UTI or OVA + Dex
group were administered UTI (100 000 Ukg·day−1, i.p.) or dexamethasone (1 mg·kg−1·day−1, i.p.) on days 21 to 27. At 24 h
after final OVA challenge, serum levels of total (A) and OVAspecific IgE (B) were quantified using ELISA kit. Means ± SD of
10 mice per group. *P < 0.05, compared with Con group.
#P < 0.05, compared with OVA alone group.
Figure S2 UTI prevents OVA-induced up-regulation or
down-regulation of cytokine mRNAs. At 24 h after final OVA
challenge, lungs were harvested. Lung tissue levels of IL-4,
IL-5 and IFN-γ mRNA were determined using qRT-PCR and
normalized to GAPDH mRNA. UTI or Dex treatment prevented IL-4 (A) and IL-5 (B) mRNA up-regulation, and IFN-γ
mRNA (C) down-regulation in OVA-sensitized and challenged mice. Means ± SD of five mice per group. *P < 0.05,
compared with control group. #P < 0.05, compared with OVA
alone group.
Figure S3 Excipients of UTI had no effects on HO1 expression and on OVA-induced oxidative stress. Control mice were
injected with saline (Con) or excipients of UTI (Excipient) at
the dose equivalent to 200 KU·kg−1 of UTI once daily for 15
days and lung tissue harvested. OVA-sensitized and challenged mice were untreated (OVA), or treated with UTI (OVA
+ UTI) or equivalent dose of excipients on days 21 to 27. At
24 h after final OVA challenge, lung tissue level of HO1
protein was determined or bronchoalveolar lavage fluid level
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(BALF) leukocyte reactive oxygen species (ROS) activity measured using DCF-DA fluorescence probe and expressed as fluorescence intensity. (A) Western blot photographs show that
excipients of UTI had no effect on basal and OVA-induced
HO1 protein expression. (B) The western blot HO1 bands
were quantified using densitometry and expressed as fold
increase over control. Means ± SD of five mice per group.
*P < 0.05, compared with Con or Excipient group. #P < 0.05,
compared with OVA or OVA + Excipient group. (C) Bar graph
shows that the excipients of UTI had no effect on basal and
OVA-induced BALF leukocyte ROS activity. Means ± SD of five
mice per group. *P < 0.05, compared with Con or Excipient
group. #P < 0.05, compared with OVA or OVA + Excipient
group.
Figure S4 Inhibition of HO1 activity abrogates the stimulatory effects of UTI on antioxidant capacities. Mice in Con,
OVA, OVA + UTI or OVA + UTI + ZnPP group were sham or
OVA-sensitized and challenged, and treated with UTI as
described above. Mice in OVA + UTI + ZnPP group were
injected with ZnPP (20 mg·kg−1·day−1, i.p.) 1 h before each
UTI administration. At 24 h after final OVA challenge, BALF
levels of glutathione (GSH, A), total antioxidant capacity
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(TAOC, B) and catalase activity (CAT, C) were measured.
Means ± SD of 10 mice per group. *P < 0.05, compared with
control group. #P < 0.05, compared with OVA alone group.
$P < 0.05, compared with OVA + UTI group.
Figure S5 Representative immunofluorescence staining
shows that UTI stimulates Nrf2 nuclear translocation. At 24 h
after final OVA challenge, lung cryosections were prepared
and IF stained with Nrf2 antibody. The specificity of Nrf2
antibody staining was confirmed using isotype control antibody. Lung sections from OVA-sensitized and challenged
mice (OVA) have an increased, and lung sections from OVA +
UTI group mice have further increased number of Nrf2/DAPI
positive nuclei (bright blue dots), indicating that UTI augments OVA-induced Nrf2 nuclear translocation. Scale bar =
20 μm.
Figure S6 EMSA photograph shows that UTI inhibits NF-κB
DNA binding activity. Mice were sensitized, challenged and
treated with UTI as described above. At 24 h after final OVA
challenge, lungs were harvested and NF-κB DNA binding
activity determined. Representative of three independent
experiments.
Table S1 Primer sequences for real time PCR.

